Modality
mAb
MOA
GLP-1ag
Target
PRMT5
Pathway
RAS/MAPK
CLL
Development Pipeline
Preclinical
Nov 2019
→ Nov 2031
PreclinicalCurrent
NCT05854101
1,588 pts·CLL
2020-12→2031-11·Active
NCT04087694
2,320 pts·CLL
2019-11→TBD·Active
3,908 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-11-085.6y awayInterim· CLL
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Preclinical
Active
Preclinical
Active
Catalysts
Interim
2031-11-08 · 5.6y away
CLL
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05854101 | Preclinical | CLL | Active | 1588 | DOR |
| NCT04087694 | Preclinical | CLL | Active | 2320 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 |